BROOKDALE SENIOR LIVING INC. (BKD): what the price requires

At today's price, BROOKDALE SENIOR LIVING INC. (BKD) is priced for today's economics sustained for ~14.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/BKD

Headline

FieldValue
TickerBKD
CompanyBROOKDALE SENIOR LIVING INC.
Current price$15.02/sh
CompositionIndependent Living 20% / Assisted Living and Memory Care 69% / CCRCs 11%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin today1.3%
Must persist for14.1y
Multiple paid208x operating income

Solve inputs: computed at a 7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3 years (computed at the 7% minimum rate; the CAPM rate 6.5% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~20.4 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.03σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative0.45x1justifies
Growth—0—

Families that justify the price: Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.0%); the inversion above states its own rate.

Per-Model Detail (n=1)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noFCF base $0.0B, growth -0% (input: historical growth), terminal g 0.5%, WACC 6.0%, 5yr projection
DCF Exit MultipleGrowth$6.872.19xnoExit EV/EBITDA: 20.9x / 22.9x / 24.9x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$33.020.45xyesP/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$8.371.79xnoRev $3.1B, growth -0% (input: historical growth; tapered), Terminal P/S: 1.0x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$0.011502.00xnoNormalized EBIT (5y avg op income, one-time charges added back) $0.02B × (1−21%) / WACC 6.0% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$0.011502.00xyesEBITDA $0.39B × sector EV/EBITDA 12.0x (excluded from median)
FCF YieldEarnings$0.011502.00xyesFCF $9.3M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$33.020.45xnoRevenue $3.15B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$4.1b
Net debt / NOPAT (after-tax)121.20x
Net debt / operating income (pre-tax)95.75x
Share count CAGR (dilution)6.4%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Brookdale's thesis is its balance sheet: about 4.06 billion dollars of net debt with interest coverage near 0.3 times, but management refinanced a large portion of its 2027 maturities out to 2033, removing the near-term wall.

The operating turnaround is real: Q1 2026 occupancy rose 280 basis points to 82.1 percent, RevPAR grew 8.2 percent, adjusted EBITDA hit 131 million dollars, and the net loss narrowed from 65 million dollars to 7 million.

The 10-K cites about one million new potential senior residents per year for the next decade, the demand tailwind behind guidance for full-year adjusted EBITDA of 502 to 516 million dollars, though the negative equity makes this a recovery option rather than a value buy.

Bull Case

Everything about Brookdale starts with the balance sheet, because the balance sheet is both the risk and, increasingly, the story. The company carries about 4.06 billion dollars of net debt against trailing operating income of only 35.7 million, a leverage profile that for years made the equity look like a call option on survival. What changed is that management spent the past several quarters defusing the most dangerous part of that stack. In the first quarter of 2026 it refinanced a significant portion of its 2027 mortgage maturities and pushed them out to 2033, removing the near-term wall that had haunted the stock. The 10-K is explicit about why this matters, warning that a default on its instruments "could cause a default under other debt and lease documents" (accession 0001332349-25-000037). Taking that cross-default risk off the table is the single most important thing a levered equity can do.

With the refinancing in hand, the operating recovery becomes visible. Occupancy rose 280 basis points year over year to 82.1 percent, revenue per available unit grew 8.2 percent, and adjusted EBITDA reached 131 million dollars, up 5.6 percent. The net loss narrowed sharply, from 65 million dollars a year earlier to 7 million. A senior-living operator is a high-fixed-cost business, so each point of occupancy drops almost straight to EBITDA; that operating leverage is exactly what is driving the turnaround.

The demand backdrop is the reason to believe the recovery has legs. The 10-K describes a demographic wave directly, citing "one million new potential residents per year for the next decade" as the senior population ages (accession 0001332349-25-000037). Brookdale is the largest operator in the country, and after years of industry oversupply the supply pipeline has thinned while demand swells. Management has signaled its own confidence by raising occupancy and EBITDA guidance and selling non-core communities for over 100 million dollars to fund the deleveraging. The bull case is a self-help story: fix the debt, fill the buildings, ride the demographics.

Bear Case

The structural truth a Brookdale holder would rather not face is that the equity sits behind 4.06 billion dollars of net debt at a company whose operating income does not cover its interest. Interest coverage is about 0.3 times. Read that plainly: the business as currently run does not earn enough to pay its lenders from operations, and the reported equity is negative. The refinancing pushed the maturities out, which is real progress, but it did not reduce the debt; it rescheduled it. The 10-K's own language captures the fragility, that a default "could cause a default under other debt and lease documents (including documents with other lenders and lessors)" (accession 0001332349-25-000037). A single operational stumble or a tightening in credit markets reintroduces the existential question the refinancing only postponed.

The valuation math is brutal once you stop using the friendly metric. On operating income the market is paying roughly 200 times, which implies the company holding growth at the fastest pace it could fund from its own profits for about fourteen years. Only about 14 percent of comparable fast-growers have sustained anything like that for a decade. The price effectively requires a flawless, multi-year execution of a turnaround in a business that has disappointed before. The 10-K also reminds investors that the industry's troubles were self-inflicted, noting that occupancy "began to decrease starting in 2016 as a result of new openings" and the resulting "oversupply and increased competitive pressures" (accession 0001332349-25-000037). The same dynamic can return if operators chase the demographic wave with new supply.

The cash reality is the final caution. Free cash flow is barely positive, near 9 million dollars, because the interest burden and maintenance capital expenditure on a large owned-and-leased real estate footprint consume almost everything the operations generate. The relative-valuation read that anchors on revenue lands above the price, but it is a price-to-sales fallback used precisely because the company has no positive earnings to value. Strip away the demographic optimism and the deleveraging narrative, and what remains is a deeply indebted, low-margin operator whose equity value depends on the debt not winning the argument.

Valuation

Brookdale is a levered equity, so the valuation has to lead with the capital structure rather than a clean multiple. Net debt of about 4.06 billion dollars against trailing operating income of 35.7 million produces an interest-coverage ratio near 0.3 times, meaning operations do not currently cover interest, and the reported equity is negative. The standard operating-income inversion is therefore unreliable here: on that basis the price reads as paying roughly 200 times operating income, which would imply holding growth at the fastest self-funded pace for about fourteen years, a figure that only signals how distorted earnings-based multiples become for a company at this stage of recovery.

The more honest yardstick is enterprise value against EBITDA and the trajectory of that EBITDA. Adjusted EBITDA reached 131 million dollars in the quarter and management guides the full year to 502 to 516 million dollars. Against a roughly 5.5 billion dollar enterprise value, that is a high but not absurd multiple for a business inflecting upward, and it is the metric the equity actually trades on. The relative-valuation read using a price-to-sales fallback lands near 33 dollars, well above the 13.63 dollar price, but that model is used only because there are no positive earnings to capitalize, so it should be weighted lightly.

The verdict is that this is a recovery option, not a value purchase. The equity is worth a multiple of EBITDA minus the debt, and the debt is large enough that small changes in EBITDA or in the cost of refinancing swing the equity sharply. The refinancing to 2033 and the rising occupancy improve the odds; the negative equity and sub-one interest coverage define the downside. The price is a bet that the EBITDA ramp and the deleveraging continue together, with little margin for either to stall.

Catalysts

The deleveraging timeline is the dominant catalyst because it governs survival. In Q1 2026 Brookdale refinanced a significant portion of its remaining 2027 mortgage maturities and extended them to 2033, and it has received over 100 million dollars of cash proceeds from community sales in 2026 to date (Simply Wall St, Brookdale 8-K). Each additional refinancing or asset sale that reduces or extends the debt is a direct catalyst for the equity, which sits behind that obligation.

The occupancy and EBITDA cadence is the operating catalyst. Q1 2026 (reported May 2026) showed consolidated occupancy up 280 basis points to 82.1 percent, RevPAR up 8.2 percent, adjusted EBITDA of 131 million dollars, and a net loss narrowed to 7 million from 65 million a year earlier; management reiterated full-year guidance of 8 to 9 percent RevPAR growth and adjusted EBITDA of 502 to 516 million dollars (TipRanks, Yahoo Finance). The monthly occupancy releases are a high-frequency read on whether the demographic-driven recovery is holding.

Sentiment reflects the tension between operations and balance sheet. The most recent analyst rating is a Buy with an 18 dollar price target, while an automated assessment rated the stock Neutral, held back by ongoing net losses and a high-risk balance sheet with negative equity (Globe and Mail). The watch items are the next debt move, the pace of occupancy gains against the 2026 guide, and whether free cash flow turns durably positive.

Peer Cohorts (Per Segment, With Filing Citations)

Independent Living / CCRCs (reported)

Assisted Living and Memory Care (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive BKD report on boothcheck